1. Market Research
  2. > Pharmaceutical
  3. > Drug Discovery and Development Market Trends
  4. > India Pharma Outlook 2016: Milestones to Watch – Growth from Exports and Domestic Getting Better, Implementation of Policies under “Make-in-India”, Overture of A New Ministry

2016 will be a crucial for drug makers and consumers. During ‘Make-in-India’ week in Mumbai, Govt. highlighted many amendments or introduction of new policies with an aim to make India as a major hub for end to end drug discovery. To boost drug discovery, to promote manufacturing of certain drugs against life threatening diseases like AIDS, and to reduce our dependence on China, the Govt. has promised to offer many incentives (exemption from excise duty or tax) and also plans to setup venture capital funds, cluster developments to strengthen pharma infrastructure / business. Other developments or initiatives include, i) The voluntary Uniform code of Pharma marketing practice will be replaced with a mandatory code by June.

This will stop the promotion of drug prior to receipt of the marketing approval and also the practice of drug makers offering gifts to doctors upon prescribing their products; ii) Concept of the ‘Online pharmacies’ is also expected to be implemented during this year; iii) Change in FDI rule where investor now invest thru Automatic route rather taking any prior regulatory approval; iv) Growth in Medical Infrastructure which will increase accessibility to drug market to improve in Tier-II towns and rural areas.

Declined growth in bulk drugs due to regulatory scrutiny and rising competition & market factors from other Asian competing nations will be compensated by geographies expansion (e.g., Lupin, Cipla, Sun pharma) and sustainable growth from Domestic formulation (e.g. Alkem, Cipla, Sun pharma, Dr Reddy), mainly from Chronic diseases’ segment, due to growth in urban population, better awareness on healthcare, and greater penetration of services. India pharma has started expanding in other regulated markets (Japan, Germany, France, Canada) and Tier-II countries (Brazil, Mexico, Venezuela, Russia, etc.). To explore further opportunities of growth, Indian pharma companies have started developing complex generics/ biosimilars. Almost all companies, among Top-20 list, have robust pipeline in this value chain, targeting primarily emerging markets; however, they are also capitalizing on their competitiveness and capabilities to enter into the regulated market.

Table Of Contents

India Pharma Outlook 2016: Milestones to Watch - Growth from Exports and Domestic Getting Better, Implementation of Policies under “Make-in-India”, Overture of A New Ministry
Aurobindo Pharma - US BUSINESS AND INJECTABLES KEYS TO GROWTH - Looking to STRENGTHEN IN OTHER GEOGRAPHY TOO
Table 1 : Aurobindo Pharma : GLOBAL REGULATORY FILINGS
Table 2 : Aurobindo Pharma KEY ANDAs APPROVAL IN 1H16
New Aeras to Watch For :

CADILA HEALTHCARE LTD : Future growth from NCE, Bio-Similars, Vaccines, Transdermal and Complex Generics

- US REMAINS THE KEY GROWTH DRIVER FOR CDH
- Table 1
Cadila Healthcare Ltd.
KEY TRANSDERMAL PRODUCTS

- ONGOING STUDIES OF LIPAGLYN IN NASH
- Clinical Data in NASH so far
- Clinical Data in NASH so far

Cipla Ltd : Consolidation of Recent Acquisitions + Geographic Expansion of the Inhaler Business

-Figure 1
Cipla Ltd.
GENERIC NEXIUM'S MARKET SHARE TREND
- Table 1
Cipla Ltd.
INVAGEN'S SELECT PARA IV OPPORTUNITIES
- Table 2
Cipla Ltd.
INVAGEN: HIGHEST MARKET SHARE PRODUCTS - TOP 5
- Annexure : Cipla Ltd.
INVAGEN'S CURRENT PRODUCTS
- DR REDDY'S LAB : Near-term Growth Muted: Strong Competition to Launched Products + No Significant Approvals + Remediation Costs related to FDA's WL
- Figure 1
Dr. Reddy's Lab
PENDING ANDAs(76) BY DOSAGE FORMand SELECT OPPORTUNITIES
- Table 1
Dr Reddy's Ltd.
FACING COMPETITION IN US: MARKET SHARE OF KEY INJECTABLES
-Figure 2
Dr. Reddy's Lab
AURIGENE: INTERNAL PIPELINE
- ANNEXURE : Key highlights of the warning letter

LUPIN LIMITED :Potential of Complex Generics and Gavis Integration Yet to Unfold
- Table 1
Lupin Limited
NET SALES MIX: 2QFY16
- Figure 1
Lupin Limited
COMBINED ENTITY: LUPIN + GAVIS
- Figure 1
Lupin Limited
COMBINED ENTITY: LUPIN + GAVIS
- Figure 2
Lupin Limited
INCREASED COMPETITION LED TO DECLINED MARKET SHARE IN US
-Table 2
Lupin Limited
US APPROVALS IN 9MFY16
- Table 3
Lupin Limited
US: SELECT UPCOMING ANDAs OPPORTUNITIES
- Annexure I
Lupin Limited
2QFY16: SALES BREAKUP, GEOGRAPHY-WISE
- Annexure III
Lupin Limited
COMBINED CAPABILITIES: GAVIS + LUPIN

NATCO PHARMA : Leading Oncology Company In India - Targeting US market with less competitive and high complex Drugs

-Table 1
NATCO Pharma
KEY ANDAs PIPELINE

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Bioinformatics Market by Sector (Molecular Medicine, Agriculture, Forensic, Animal, Research & Gene Therapy), Product (Sequencing Platforms, Knowledge Management & Data Analysis) & Application (Genomics, Proteomics & Metabolomics) - Global Forecast to 202

Bioinformatics Market by Sector (Molecular Medicine, Agriculture, Forensic, Animal, Research & Gene Therapy), Product (Sequencing Platforms, Knowledge Management & Data Analysis) & Application (Genomics, Proteomics & Metabolomics) - Global Forecast to 202

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global bioinformatics market is projected to reach USD 16.18 billion by 2021 from USD 6.21 billion in 2016, growing at a CAGR of 21.1% during the forecast period. In this report, the bioinformatics ...

Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

  • $ 5650
  • Industry report
  • August 2016
  • by MarketsandMarkets

The global clinical trial management system (CTMS) market is estimated to grow at a CAGR of 11.5% from 2016 to 2021, to reach USD 920.0 billion by 2021. The adoption of CTMS software is on the rise across ...

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global CRO services market is estimated to grow at a CAGR of 7.4% from 2016 to 2021, to reach USD 41.86 billion by 2021 from USD 29.29 billion in 2016. Growth in this market is primarily attributed ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.